A novel conjugate of low-molecular-weight heparin and Cu,Zn-superoxide dismutase: study on its mechanism in preventing brain reperfusion injury after ischemia in gerbils.
Low-molecular-weight heparin (LMWH) and Cu,Zn-superoxide dismutase (SOD) were extensively investigated on preventing brain reperfusion injury after ischemia (BRII) in the past few years and both exhibited some advantages as well as limits in practice. To explore whether chemical modification for LMWH and SOD can lead to improved bioactivity,in our present study, we examined the efficacy of LMWH conjugated SOD (LMWH−SOD) in the model of BRII gerbils. Ischemia/reperfusion was performed for 5 min by clamping the bilateral common carotid arteries of gerbils. LMWH−SOD, SOD and the mixture of LMWH and SOD (LMWH+SOD) were administered intravenously to corresponding animals just before ischemia. 24 h after reperfusion, serum malondialdehyde (MDA) content and SOD activity were measured, the expression of intercellular adhesion molecule-1 (ICAM-1) was examined by immunohistochemistry, and the brain sections were processed for Nissl staining and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end-labeling.The results showed that LMWH−SOD significantly lowered MDA content (P<0.001, versus SOD and LMWH+SOD) and elevated SOD activity (P<0.05, versus SOD and LMWH+SOD) in the serum of BRII gerbils. Immunohistochemical results indicated ICAM-1 positive staining was lighter, pyramidal cells of hippocampal CA1 region were more regular and the changes in cell edema were minor, and apoptosis of hippocampal cells was milder in LMWH−SOD treated animals than in SOD or LMWH+SOD treated animals, untreated BRII animals and sham-operated animals. The results suggest that the novel LMWH−SOD conjugate can inhibit upregulation of ICAM-1 and prevent neuronal cell apoptosis in BRII gerbils, and the LMWH−SOD conjugate has better anti-inflammatory and neuroprotective effects in BRII than native SOD and the mixture of LMWH and SOD.
Qi
Jingzong
J
Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, Shandong, China.
Li
Yizhao
Y
Zhang
Hongwei
H
Cheng
Yanna
Y
Sung
Yongfu
Y
Cao
Jichao
J
Zhao
Ying
Y
Wang
Fengshan
F
D061605:Administration, Intravenous; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002545:Brain Ischemia / Q000473:pathology / Q000503:physiopathology*; D004195:Disease Models, Animal; D005849:Gerbillinae; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage*; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D008315:Malondialdehyde / Q000097:blood; D009474:Neurons / Q000187:drug effects / Q000473:pathology / Q000502:physiology; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D011897:Random Allocation; D015427:Reperfusion Injury / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000008:administration & dosage* / Q000097:blood
D006495:Heparin, Low-Molecular-Weight; D018696:Neuroprotective Agents; D018799:Intercellular Adhesion Molecule-1; D008315:Malondialdehyde; D013482:Superoxide Dismutase